Diaceutics (LON:DXRX) Releases Earnings Results

Diaceutics (LON:DXRX) released its earnings results on Tuesday. The company reported GBX (3.27) earnings per share for the quarter, Digital Look Earnings reports. Diaceutics had a net margin of 0.25% and a return on equity of 0.25%.

Diaceutics Stock Up 2.9%

Shares of DXRX opened at GBX 197 on Thursday. Diaceutics has a one year low of GBX 125 and a one year high of GBX 197. The company has a market cap of £167.18 million, a P/E ratio of 1,790.91 and a beta of 0.88. The company has a debt-to-equity ratio of 2.85, a current ratio of 3.43 and a quick ratio of 9.92. The firm has a 50 day simple moving average of GBX 146.97 and a two-hundred day simple moving average of GBX 151.24.

Wall Street Analysts Forecast Growth

Separately, Canaccord Genuity Group reaffirmed a “buy” rating and issued a GBX 215 price target on shares of Diaceutics in a research note on Tuesday. Two analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of GBX 215.

Diaceutics Company Profile

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.